Repligen (RGEN)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-14
$168.00+1.71%
Close 2026-09-14 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-14
Research Workspace
Put RGEN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Increase adjusted EPS to $1.97-$2.05 in FY26: FY26 EPS guidance $2.03-$2.09 vs target $1.97-$2.05.
View ThesisRevenue growth is accelerating — up about 16% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look high — the market is pricing in about 231% growth a year, above the roughly 18% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 40% in its worst 12-month stretch.
View RiskRepligen's growth depends on achieving 10.5%-13.5% organic revenue growth in FY26. Revenue grew 12% year over year, and the last quarter beat expectations. It trades at 12× price-to-sales, in line with its peer median, but the market prices in more growth than forecast. If RGEN cuts guidance after recently raising it, that could harm credibility. Peer multiples imply a price about 81% below where it trades (it looks expensive on this basis). Our read is provisional.
Trailing returns as of 2026-09-14. RGEN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 23 analysts currently covering RGEN (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare RGEN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| RGEN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put RGEN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand cell therapy market presence via BioLife acquisition
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
BioLife merger enhances cell therapy market presence.
Advances: Achieve 10.5%-13.5% organic revenue growth in FY26
Indicates growth potential aligns with revenue objectives.
Advances: Achieve 10.5%-13.5% organic revenue growth in FY26
Revenue growth supports organic growth target for FY26.
Threatens: Increase adjusted EPS to $2.03-$2.09 in FY26
Mixed earnings could hinder EPS growth objective.
Threatens: Expand cell therapy market presence via BioLife acquisition
Uncertainty around BioLife acquisition could hinder growth objectives.
Advances: Expand cell therapy market presence via BioLife acquisition
BioLife deal enhances cell therapy market presence.
Advances: Achieve 9%-13% organic revenue growth in FY26
Revenue growth and guidance raise support growth objectives.
Advances: Expand cell therapy market presence via BioLife acquisition
BioLife acquisition supports cell therapy market expansion.
